The Congressionally Directed Medical Research Programs (CDMRP), are supported by funds allocated by Congress for biomedical research in response to the needs of the American people and military. With a FY2018 budget of over $975 million, these funds will go towards supporting R&D efforts in various stages of development. Some research areas covered include Breast Cancer, Parkinson’s, and Multiple Sclerosis as well as additional Peer Reviewed topics covering Alzheimer’s, Cancer, and others.
In this webinar, we discuss the various programs, the process for applying, guidelines, key success components and insight into increasing chances for award.
NIH alone awards roughly $6B annually to Cancer related R&D grants and contracts. The scope of funding support covers much of the R&D cycle, from basic research, through pre-clinical activities and early phase clinical trials.
In this webinar, we discuss key cancer related opportunities, focusing on the new set of solicitations from the National Cancer Institute (NCI) and the soon to be released CDMRPs (DoD) that are available for life science organizations.
In a world in which both medical diagnostics and therapies are shifting towards minimally invasive technologies, it is not surprising that steadily increasing non-dilutive funding is available for innovative medical device companies.
The scope of funding support covers the entire R&D cycle, from early stage exploratory and discovery work all the way to late stage clinical research and validation.
In this webinar, FreeMind experts discuss the latest trends at the NIH and the funding opportunities available with respect to medical devices.
Non-US applicants are eligible for the majority of the non-dilutive pockets of money including NIH, Department of Defense, BARDA etc. Currently, the National Institutes of Health (NIH) are actively funding over 1000 projects in the excess of $1.3B, taking place outside the US and awarded to non-US applicant organizations. And, when taking into account collaborations and partnerships between domestic and foreign entities, the funded R&D dollars outside the US even exceed the above.
In this presentation, we provide insight into the non-dilutive funding landscape with an emphasis on the NIH, Department of Defense and other government agencies. FreeMind experts will describe the various pockets of money available for non-US applicants, potential for funding, and means to maximize chances for award.
Within the non-dilutive funding space one can find pockets of money in the billions of dollars directed at unmet medical needs related to CNS/PNS ailments. The scope of funding support covers much of the R&D cycle from proof of concept to late stage clinical.
In this webinar, we discuss key CNS/PNS related funding opportunities, with an emphasis on NINDS, NIA, and NIMH.
In order to maximize your funding potential, all sources of funding must be considered, including the less traditional ones.
The NIH’s R21 mechanism aims to fund very early stage proof of concept type programs of up to 2 years at about $300,000, whereas the R01 mechanism is more suitable for longer programs of up to 5 years, totaling close to $3,000,000. Other agencies such as the Department of Defense, BARDA, FDA, and NSF also have awards for research in the life sciences.
In this webinar, we share insight into alternatives to the classic SBIR/STTR mechanisms. We will discuss methodology for establishing both responsiveness as well as competitiveness and how to increase chances for award.
SBIR/STTR awards account for over $780,000,000 awarded per year by NIH alone. These are excellent sources of funding aimed at promoting R&D activities of US-based small businesses as well as collaborations with Academics.
SBIR/STTRs differ from traditional NIH mechanisms in that they are highly product driven and ultimately are seeking commercialization of novel therapies, diagnostics, devices, etc.
In this webinar, we discuss process for applying, guidelines, key success components and insight into increasing chances for award.
Every year, US-based non-dilutive sources of funding award billions of dollars towards clinical stage research in the Life Sciences.
Funding is available for clinical stage funding across scientific fields including Infectious Diseases, Neurosciences, Cardiovascular, and many more. These funds come from multiple Institutes within the NIH, such as NIAID, NIAMS, NIDDK, from BARDA, and from the DOD.
In this webinar, we discuss the process for applying, guidelines, key success components and insight into increasing chances for award.